Bristol Myers Squibb announced on May 29, 2026 that mezigdomide, a cereblon E3 ligase modulator (CELMoD) agent, reduced disease progression or death risk by 52% in the SUCCESSOR-2 trial of relapsed/refractory multiple myeloma patients. Median progression-free survival reached 18 months versus 8.3 months for standard treatment alone. The experimental oral drug achieved an 80.2% overall response rate when combined with carfilzomib and dexamethasone.
SUCCESSOR-2 trial results
- ▪Median progression-free survival was 18 months for patients who received mezigdomide in the SUCCESSOR-2 trial versus 8.3 months for the control arm
- ▪Overall survival data from the SUCCESSOR-2 trial is not yet available as of May 29, 2026
- ▪The overall response rate was 80.2% for patients on the mezigdomide regimen in the SUCCESSOR-2 trial, while 53.4% responded to the standard therapy
- ▪83.7% of mezigdomide patients in the SUCCESSOR-2 trial had significant adverse events compared with 56.5% for the control group
- ▪27% of patients who received mezigdomide in the SUCCESSOR-2 trial had a complete response, roughly triple the number compared to the control group
- ▪Bristol Myers Squibb announced on May 29, 2026 that mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to other treatments
- ▪The SUCCESSOR-2 trial results are being presented at the annual American Society of Clinical Oncology meeting in Chicago in May 2026
- ▪Bristol Myers Squibb's SUCCESSOR-2 trial showed that mezigdomide added to carfilzomib and dexamethasone reduced the risk of disease progression or death by 52% compared to the standard treatment alone in multiple myeloma patients
Mezigdomide drug mechanism
- ▪Iberdomide is another myeloma treatment Bristol Myers Squibb is developing that belongs to the cereblon E3 ligase modulator (CELMoD) class of drugs
- ▪Mezigdomide is an experimental oral drug developed by Bristol Myers Squibb
- ▪The most common adverse event from mezigdomide treatment was neutropenia, abnormally low levels of a type of white blood cell
- ▪Mezigdomide belongs to a class of drugs called cereblon E3 ligase modulator (CELMoD) agents
- ▪Mezigdomide, as an oral medicine, could easily be used in community oncology clinics where most myeloma patients are treated
Generic competition replacement strategy
- ▪The U.S. FDA is expected to make an approval decision on iberdomide in August 2026
- ▪Carfilzomib is sold as Kyprolis by Amgen
- ▪Bristol Myers Squibb sees mezigdomide and iberdomide replacing older Bristol Myers Squibb medicines Revlimid and Pomalyst, which are facing generic competition, in later lines of treatment
Story comments
Loading comments…